Pfizer ( ($PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock. Pfizer Inc. is actively advancing its ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is initiating a Phase 1 clinical study titled A PHASE 1, ...

Pfizer has earned a consensus rating of “Moderate Buy” from fifteen analysts, with only one calling it a “sell.” The average ...

Pfizer (NYSE:PFE) recently announced positive topline results from its Phase 3 BASIS study for HYMPAVZI™ and declared a third ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment ...

Pfizer's cost-cutting boosts earnings despite revenue miss. Discover its growth strategy, strong drug portfolio & potential ...

AbbVie ABBV has built a substantial oncology franchise. Initially anchored by blood cancer drugs Imbruvica and Venclexta, the ...